Zhizhu decoction alleviates slow transit constipation by regulating aryl hydrocarbon receptor through gut microbiota
CONTEXT: Slow transit constipation (STC), the most common type of constipation, seriously affects the life of patients. Zhizhu decoction (ZZD), a traditional Chinese medicine compound, has is effective against functional constipation, but the mechanism is still unclear.
OBJECTIVE: This research explores the mechanism of ZZD on STC from the perspective of metabolomics and gut microbiota.
MATERIALS AND METHODS: Fifty-four C57BL/6 mice were randomly divided into six groups (n = 9): control (control); STC (model); positive control (positive); low-dose (5 g/kg; L-ZZD), medium-dose (10 g/kg; M-ZZD), and high-dose (20 g/kg; H-ZZD) ZZD treatment. Following treatment of mice with ZZD for two weeks, the changes in intestinal motility, colon histology, intestinal neurotransmitters, and aryl hydrocarbon receptor (AHR) pathway determined the effects of ZZD on the pathophysiology of STC. LC-MS targeting serum metabolomics was used to analyze the regulation of ZZD on neurotransmitters, and 16S rRNA high-throughput sequencing was used to detect the regulation of the gut microbiome.
RESULTS: ZZD had the highest content of naringin (6348.1 mg/L), and could significantly increase the 24 h defecations (1.10- to 1.42-fold), fecal moisture (1.14-fold) and intestinal transport rate (1.28-fold) of STC mice, increased the thickness of the mucosal and muscular tissue (1.18- to 2.16-fold) and regulated the neurotransmitters in the colon of STC mice. Moreover, ZZD significantly activated the AHR signaling pathway, and also affected the composition of gut microbiota in STC mice.
DISCUSSION AND CONCLUSIONS: The beneficial effect and the possible mechanism of ZZD on STC could provide a theoretical basis for the broader clinical application of ZZD.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Pharmaceutical biology - 61(2023), 1 vom: 19. Dez., Seite 111-124 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wen, Yong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
16S rRNA sequencing |
|---|
| Anmerkungen: |
Date Completed 26.12.2022 Date Revised 04.09.2023 published: Print ErratumIn: Pharm Biol. 2023 Dec;61(1):1413. - PMID 37665171 Citation Status MEDLINE |
|---|
| doi: |
10.1080/13880209.2022.2157020 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350738254 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350738254 | ||
| 003 | DE-627 | ||
| 005 | 20231226045655.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13880209.2022.2157020 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1169.xml |
| 035 | |a (DE-627)NLM350738254 | ||
| 035 | |a (NLM)36562308 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wen, Yong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Zhizhu decoction alleviates slow transit constipation by regulating aryl hydrocarbon receptor through gut microbiota |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.12.2022 | ||
| 500 | |a Date Revised 04.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a ErratumIn: Pharm Biol. 2023 Dec;61(1):1413. - PMID 37665171 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a CONTEXT: Slow transit constipation (STC), the most common type of constipation, seriously affects the life of patients. Zhizhu decoction (ZZD), a traditional Chinese medicine compound, has is effective against functional constipation, but the mechanism is still unclear | ||
| 520 | |a OBJECTIVE: This research explores the mechanism of ZZD on STC from the perspective of metabolomics and gut microbiota | ||
| 520 | |a MATERIALS AND METHODS: Fifty-four C57BL/6 mice were randomly divided into six groups (n = 9): control (control); STC (model); positive control (positive); low-dose (5 g/kg; L-ZZD), medium-dose (10 g/kg; M-ZZD), and high-dose (20 g/kg; H-ZZD) ZZD treatment. Following treatment of mice with ZZD for two weeks, the changes in intestinal motility, colon histology, intestinal neurotransmitters, and aryl hydrocarbon receptor (AHR) pathway determined the effects of ZZD on the pathophysiology of STC. LC-MS targeting serum metabolomics was used to analyze the regulation of ZZD on neurotransmitters, and 16S rRNA high-throughput sequencing was used to detect the regulation of the gut microbiome | ||
| 520 | |a RESULTS: ZZD had the highest content of naringin (6348.1 mg/L), and could significantly increase the 24 h defecations (1.10- to 1.42-fold), fecal moisture (1.14-fold) and intestinal transport rate (1.28-fold) of STC mice, increased the thickness of the mucosal and muscular tissue (1.18- to 2.16-fold) and regulated the neurotransmitters in the colon of STC mice. Moreover, ZZD significantly activated the AHR signaling pathway, and also affected the composition of gut microbiota in STC mice | ||
| 520 | |a DISCUSSION AND CONCLUSIONS: The beneficial effect and the possible mechanism of ZZD on STC could provide a theoretical basis for the broader clinical application of ZZD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 16S rRNA sequencing | |
| 650 | 4 | |a Intestinal neurotransmitters | |
| 650 | 4 | |a functional constipation | |
| 650 | 4 | |a intestinal motility | |
| 650 | 4 | |a metabolomics | |
| 650 | 7 | |a Receptors, Aryl Hydrocarbon |2 NLM | |
| 650 | 7 | |a RNA, Ribosomal, 16S |2 NLM | |
| 700 | 1 | |a Zhan, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Shiyu |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Fang |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Rong |e verfasserin |4 aut | |
| 700 | 1 | |a Kong, Pengfei |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Xuegui |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceutical biology |d 1997 |g 61(2023), 1 vom: 19. Dez., Seite 111-124 |w (DE-627)NLM097504416 |x 1744-5116 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2023 |g number:1 |g day:19 |g month:12 |g pages:111-124 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/13880209.2022.2157020 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2023 |e 1 |b 19 |c 12 |h 111-124 | ||